

# ForPatients

by Roche

Colorectal Cancer (CRC)

## Study of Cobimetinib in Combination With Atezolizumab and Bevacizumab in Participants With Gastrointestinal and Other Tumors

**Trial Status**  
Completed

**Trial Runs In**  
2 Countries

**Trial Identifier**  
NCT02876224 2016-000584-16  
CO39083

---

The source of the below information is the publicly available website [ClinicalTrials.gov](https://clinicaltrials.gov). It has been summarised and edited into simpler language.

### *Trial Summary:*

This is an open-label, multicenter, single-arm, two-stage, Phase Ib study designed to assess the safety, tolerability, and pharmacokinetics of oral cobimetinib with intravenous (IV) atezolizumab and bevacizumab in participants with metastatic colorectal cancer (mCRC) who have received and progressed on at least one prior line of therapy that contained a fluoropyrimidine and oxaliplatin or irinotecan. There are two stages in this study: Stage 1 (safety run-in phase) and Stage 2 (dose expansion phase with two cohorts, an expansion cohort and a biopsy cohort).

**Hoffmann-La Roche**  
Sponsor

**Phase 1**  
Phase

---

**NCT02876224 2016-000584-16 CO39083**  
Trial Identifiers

---

### *Eligibility Criteria:*

**Gender**  
All

**Age**  
≥ 18 Years

**Healthy Volunteers**  
No

---